Hypofractionation for prostate cancer: tested and proven.
Publication
, Journal Article
Lee, WR
Published in: Lancet Oncol
August 2016
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Lancet Oncol
DOI
EISSN
1474-5488
Publication Date
August 2016
Volume
17
Issue
8
Start / End Page
1020 / 1022
Location
England
Related Subject Headings
- Radiation Dose Hypofractionation
- Prostatic Neoplasms
- Oncology & Carcinogenesis
- Male
- Humans
- Dose Fractionation, Radiation
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Lee, W. R. (2016). Hypofractionation for prostate cancer: tested and proven. Lancet Oncol, 17(8), 1020–1022. https://doi.org/10.1016/S1470-2045(16)30150-4
Lee, W Robert. “Hypofractionation for prostate cancer: tested and proven.” Lancet Oncol 17, no. 8 (August 2016): 1020–22. https://doi.org/10.1016/S1470-2045(16)30150-4.
Lee WR. Hypofractionation for prostate cancer: tested and proven. Lancet Oncol. 2016 Aug;17(8):1020–2.
Lee, W. Robert. “Hypofractionation for prostate cancer: tested and proven.” Lancet Oncol, vol. 17, no. 8, Aug. 2016, pp. 1020–22. Pubmed, doi:10.1016/S1470-2045(16)30150-4.
Lee WR. Hypofractionation for prostate cancer: tested and proven. Lancet Oncol. 2016 Aug;17(8):1020–1022.
Published In
Lancet Oncol
DOI
EISSN
1474-5488
Publication Date
August 2016
Volume
17
Issue
8
Start / End Page
1020 / 1022
Location
England
Related Subject Headings
- Radiation Dose Hypofractionation
- Prostatic Neoplasms
- Oncology & Carcinogenesis
- Male
- Humans
- Dose Fractionation, Radiation
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis